It is known that PD‐L1 on cancer cells engages with PD‐1 on immune cells, contributing to cancer immune escape, and blocking PD‐1/PD‐L1 interactions through immunotherapy can reactivate the anti‐tumour immune response. The gene discussed is CD274; the disease is neoplasm.